

How is the Innovative Medicines Initiative helping in the EU response to COVID-19?

As part of the EU response to the coronavirus pandemic, the Innovative Medicines Initiative is mobilising **€117 million in public and private funding** to 8 research projects selected from nearly 150 proposals.

The selected research projects will cover
2 vital categories of research:

 **diagnostics**
and **treatments** 

Total funding amount:

€117 million



IMI contribution:
€72 million

More than **40**
universities and
public
research
bodies



and
40 private
companies,

including
21 SMEs



Number of
projects
selected for
funding:

8



Project partners
include
philanthropic
foundations
and **charities**



Contribution
from EFPIA,
IMI Associated Partners
& other organisations:
€45 million

Over **90 partners**
selected from
18 countries



For more information,
visit imi.europa.eu
or follow  @imi_ju
#IMICarryTheTorch



What research will be funded?



TREATMENTS: selected projects

CARE will explore whether existing drugs could be effective as treatments for COVID-19, and develop new drugs specially designed to tackle the SARS-CoV-2 virus. With 36 partners, the aim is to launch clinical trials of the most promising drug candidates.

IMPENTRI will run a randomised, double-blind clinical trial to properly test the efficacy of the generic drug imatinib as a treatment for COVID-19 patients with severe lung inflammation.

MAD-COV 2 will study the molecular details of the SARS-CoV-2 virus and use their findings to develop new COVID-19 treatments.

WHAT ELSE IS IMI DOING?

Since 2008, IMI has funded 150 research projects, some of which are currently contributing to the effort to find solutions to the coronavirus pandemic. While some of the projects are working on infectious and zoonotic diseases, others are concerned with data management and antimicrobial resistance. They are sharing their tools, expertise, and networks created as part of IMI-funded research to contribute to the wider EU response. Find out more on our website.



DIAGNOSTICS: selected projects

COVID-RED will combine expertise in clinical epidemiology with digital devices like wearables and mobile apps to rapidly and reliably detect cases so that they can be prioritised for testing.

DECISION will work on a low-cost, high-quality, miniaturised, disposable molecular diagnostic system that will make it possible to test patients with laboratory quality performance pretty much anywhere and give them their results in minutes.

DRAGON will apply artificial intelligence and machine learning to create a decision support system for better and more rapid diagnosis and prognosis. Citizens and patients will be involved in the development of the system.

KRONO aims to deliver a simple test that can be used in a doctor's surgery (or even at a patient's home) and would deliver results in just 40 minutes

RAPID-COVID aims to develop a diagnostic test that can simultaneously detect SARS-CoV-2 as well as 30 other common respiratory bacteria and viruses, to ensure COVID-19 patients are isolated quickly and that all patients receive the right treatment, avoiding unnecessary use of antibiotics.

For more information,
visit imi.europa.eu
or follow  @imi_ju
#IMICarryTheTorch



efpia

Luxembourg: Publications Office of the European Union, 2020

© Innovative Medicines Initiative, 2020

Images: © iStock.com/da-voooda;

© iStock.com/invincible_bulldog;

© iStock.com/Oleksandra Klestova

ISBN 978-92-95207-39-4

doi:10.2879/392960

FS-01-20-279-EN-N



innovative
medicines
initiative

